RWD21 Immunoglobulin a Nephropathy Patient Reported Health Utility and Quality of Life: Evidence from Real-World Data

Immunoglobulin A nephropathy (IgAN) is a rare kidney disease with an annual incidence of ∼25/1000000 worldwide. Approximately 50% of IgAN patients with proteinuria ≥1 g/day progress to kidney failure within 15 years. There are limited published health related quality of life (HRQoL) data from IgAN patients in clinical practice to date, here we report results from a multi-country study and describe patient-reported health utility and QoL split by proteinuria and estimated glomerular filtration rate (eGFR).